BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension



Status:Active, not recruiting
Conditions:High Blood Pressure (Hypertension), High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:4/6/2019
Start Date:March 12, 2009
End Date:November 29, 2019

Use our guide to learn which trials are right for you!

Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934)
will be asked to participate in this long term extension study with BAY63-2521.


Inclusion Criteria:

- Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1

Exclusion Criteria:

- Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as
related to BAY63-2521 are not allowed to participate in the extension trial.
We found this trial at
11
sites
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Capital Federal,
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
El Paso, TX
Click here to add this to my saved trials
?
mi
from
Fairfield, OH
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials